4521 — KAKEN PHARMACEUTICAL Share News
0.000.00%
Last trade - 00:00- ¥145bn
- ¥91bn
- ¥77bn
Corbus Pharma: Up after Cantor says bullish on Kaken deal
Table: Kaken Pharmaceutical - 6-MTH group results
Brief: Kaken Pharmaceutical says distribution agreement for Clenafin in Hong Kong and Macau
Table: Kaken Pharmaceutical -Q1 group results
Table: Kaken Pharmaceutical -2017/18 group results
Brief: Valeant Announces Licensing Agreement With Kaken Pharma For Psoriasis Treatment
Table: Kaken Pharmaceutical - 9-MTH group results
Brief: Kaken Pharmaceutical signs exclusive distribution agreement for Clenafin/Jublia in Taiwan
Table: Kaken Pharmaceutical - 6-MTH group results
Table: Kaken Pharmaceutical -Q1 group results
Table: Kaken Pharmaceutical -2016/17 group results
Brief: Acrux says U.S. Patent and Trademark Office institutes IPR proceeding against a U.S. Patent
Table: Kaken Pharmaceutical -2016/17 group forecast
Table: Kaken Pharmaceutical -9-MTH group results
Table: Kaken Pharmaceutical -6-MTH group results
Brief: Kaken Pharmaceutical gets domestic manufacture and marketing approval for periodontium regeneration medicine
Table: Kaken Pharmaceutical -Q1 group results
promote allergic medicine with Kyorin Holdings unit
Brief: Kaken Pharmaceutical appoints ARK MEIJI AUDIT & Co. as auditor